Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials

Value in Health

Volumn 18, Issue 2, 2015, Pages 234-249

  Cope, Shannon ^a   Clemens, Andreas ^b,c   Hammès, Florence ^d   Noack, Herbert ^b   Jansen, Jeroen P ^e  

^a MAPI Consultancy   (Canada)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d BOEHRINGER INGELHEIM   (France)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atrial fibrillation; network meta analysis; new oral anticoagulant; systematic review

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; CANADA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; META ANALYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; ATRIAL FIBRILLATION; ORAL DRUG ADMINISTRATION; PROCEDURES; STANDARDS; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TREATMENT OUTCOME;

EID: 84925013124     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.10.012     Document Type: Article

References (76)

1. I.M. Danelich, B.N. Reed, and I.B. Hollis Clinical update on the management of atrial fibrillation Pharmacotherapy 33 2013 422 446
2. J. Heeringa, D.A. van der Kuip, and A. Hofman Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study Eur Heart J 27 2006 949 953
3. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
4. E.M. Hylek, A.S. Go, and Y. Chang Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 2003 1019 1026
5. National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London: Royal College of Physicians, 2006. Available from: http://www.nice.org.uk/nicemedia/live/10982/30055/30055.pdf. [Accessed September 22, 2013].
6. J. Finsterer, and C. Stollberger Strategies for primary and secondary stroke prevention in atrial fibrillation Neth J Med 66 2008 327 333
7. R.G. Hart, and J.L. Halperin Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention Am Intern Med 131 1999 688 695
8. G.W. Albers, J. Dalen, and A. Laupacis Antithrombotic therapy in atrial fibrillation Chest 119 Suppl 2001 194S 206S
9. J. Hirsh, T.E. Warkentin, and S.G. Shaughnessy Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety Chest 119 1, Suppl. 2001 S64 S94
10. M. O'Donnell, and J.I. Weitz Novel antithrombotic therapies for the prevention of stroke in patients with atrial fibrillation Am J Manag Care 10 3, Suppl. 2004 S72 S82
11. L. Bellamy, N. Rosencher, and B.I. Eriksson Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate Patient Prefer Adherence 3 2009 173 177
12. P.J. Zimetbaum, A. Thosani, and H.T. Yu Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 123 2010 446 453
13. I.M. Ogilvie, N. Newton, and S.A. Welner Underuse of oral anticoagulants in atrial fibrillation: a systematic review Am J Med 123 2010 638 645
14. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
15. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Newly identified events in the RE-LY trial N Engl J Med 363 2010 1875 1876
16. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
17. C.B. Granger, J.H. Alexander, and J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
18. A.E. Ades A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence Stat Med 22 2003 2995 3016
19. G. Lu, and A.E. Ades Combination of direct and indirect evidence in mixed treatment comparisons Stat Med 23 2004 3105 3124
20. J.P. Jansen, B. Crawford, G. Bergman, and W. Stam Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons Value Health 11 2008 956 964
21. J.P. Jansen, R. Fleurence, and B. Devine Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1 Value Health 14 2011 429 437
22. Wells GA, Sultan SA, Chen L, et al. Indirect evidence: indirect treatment comparisons in meta-analysis. 2009. Available from: http://webcache.googleusercontent.com/search?q=cache:LvF0Ql-sLBAJ:www.cadth.ca/en/products/methods-and-guidelines/publication/884+&cd=1&hl=en&ct=clnk&gl=ca. [Accessed September 22, 2013].
23. A.M. Glenny, D.G. Altman, and F. Song Indirect comparisons of competing interventions Health Technol Assess 9 2005 1 134
24. Schöttker B, Luhmann D, Boulkheimair D, Raspe H. Indirekte vergleiche von therapieverfahren. 2009. Available from: portal.dimdi.de/de/hta/hta-berichte/hta243-bericht-de.pdf. [Accessed September 22, 2013].
25. Cucherat M, Izard V. Les comparaisons indirectes Méthodes et validité. 2009. Available from: http://www.has-sante.fr/portail/jcms/c-998796/fr/les-comparaisons-indirectes-methodes-et-validite. [Accessed September 22, 2013].
26. A. Bafeta, L. Trinquart, R. Seror, and P. Ravaud Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review BMJ 347 2013 f3675
27. A.E. Ades, D.M. Caldwell, and S. Reken Evidence synthesis for decision making: a reviewer's checklist Med Decis Making 33 2013 679 691
28. J.P. Jansen, T. Trikalinos, and J.C. Cappelleri Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report Value Health 17 2014 157 173
29. Adam SS, McDuffie JR, Ortel TL, Williams JW. Comparative effectiveness of warfarin and newer oral anticoagulants for the long-term prevention and treatment of arterial and venous thromboembolism (VA-ESP Project #09-010). 2012. Available from: http://www.ncbi.nlm.nih.gov/books/NBK97541/. [Accessed September 22, 2013].
30. A. Banerjee, D.A. Lane, C. Torp-Pedersen, and N.e.t. Lip GYH. clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study Thromb Haemost 107 2012 584 589
31. Wells G, Coyle D, Cameron C, et al. Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with arterial fibrillation. 2012. Available from: http://cadth.ca/media/pdf/NOAC-Therapeutic-Review-final-report.pdf. [Accessed September 22, 2013].
32. D. Capodanno, P. Capranzano, V. Calvi, and C. amburino Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients Int J Cardiol 167 2013 1237 1241
33. F. Dentali, N. Riva, and M. Crowther Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature Circulation 126 2012 2381 2391
34. Edwards A, Hamilton V, Nherera L, et al. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (HTA Programme Project #10/75 2011). 2011. Available from: www.nice.org.uk/nicemedia/live/13746/59295/59295.pdf. [Accessed September 22, 2013].
35. G. Ntaios, V. Papavasileiou, and H.C. Diener Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials Stroke 43 2012 3298 3304
36. L.H. Rasmussen, T.B. Larsen, and T. Graungaard Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis BMJ 345 2012 e7097
37. Spackman E, Burch J, Faria R, et al. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a single technology appraisal. 2011. Available from: www.nice.org.uk/nicemedia/live/12225/55919/55919.pdf. [Accessed September 21, 2013].
38. K. Uchino, and A.V. Hernandez Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials Arch Intern Med 172 2012 397 402
39. Coleman CI, Phung OJ, Cappelleri JC, et al. Use of Mixed Treatment Comparisons in Systematic Reviews: Methods Research Report (Prepared by the University of Connecticut/Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I; AHRQ Publication No. 12-EHC119-EF). Rockville, MD: Agency for Healthcare Research and Quality, 2012. Available from: http://www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=1238. [Accessed September 22, 2013].
40. K.H. Mak, and K.H. Mak Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials BMJ Open 2 2012 1 12
41. C.S. Miller, S.M. Grandi, and A. Shimony Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Am J Cardiol 110 2012 453 460
42. J. Harenberg, and C. Weiss Clinical trials with new oral anticoagulants: additive value of indirect comparisons also named network meta-analyses Hamostaseologie 33 2013 62 70
43. W.L. Baker, O.J. Phung, W.L. Baker, and O.J. Phung Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation Circ Cardiovasc Qual Outcomes 5 2012 711 719
44. J. Harenberg, S. Marx, and H.C. Diener Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Int Angiol 31 2012 330 339
45. A.R. Kansal, M. Sharma, and C. Bradley-Kennedy Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Thromb Haemost 108 2012 672 682
46. G.Y.H. Lip, T.B. Larsen, F. Skjoth, and L.H. Rasmussen Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation J Am Coll Cardiol 60 2012 738 746
47. S. Mantha, and J. Ansell An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation Thromb Haemost 108 2012 476 484
48. N.S. Roskell, G.Y.H. Lip, and H. Noack Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate Thromb Haemost 104 2010 1106 1115
49. S. Schneeweiss, J.J. Gagne, and A.R. Patrick Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation Circ Cardiovasc Qual Outcomes 5 2012 480 486
50. L. Testa, M. Agnifili, and R.A. Latini Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation QJM 105 2012 949 957
51. M.D. Ezekowitz, P.A. Reilly, and G. Nehmiz Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study) Am J Cardiol 100 2007 1419 1426
52. S. Ogawa, Y. Shinohara, and K. Kanmuri Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation - The ARISTOTLE-J study Circ J 75 2011 1852 1859
53. M. Hori, M. Matsumoto, and N. Tanahashi Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation Circ J 76 2012 2104 2111
54. S.J. Connolly, J. Eikelboom, and C. Joyner Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
55. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
56. J.P.T. Higgins, D.G. Altman, and P.C. Gøtzsche The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
57. NHS Quality Improvement Scotland. SIGN 50: a guideline developer's handbook. Available from: www.sign.ac.uk/pdf/sign50.pdf. [Accessed September 22, 2013].
58. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews (AHRQ publication no. 10(11)-EHC063-EF). Rockville, MD: Agency for Healthcare Research and Quality, 2011. Available from: http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318. [Accessed September 22, 2013].
59. J.P. Jansen, C.H. Schmid, and G. Salanti Direct acyclic graphs can help understand bias in indirect and mixed treatment comparisons J Clin Epidemiol 65 2012 798 807
60. S.G. Thompson, and J.P. Higgins How should meta-regression analyses be undertaken and interpreted? Stat Med 21 2002 1559 1573
61. H.R. Buller, J.L. Halperin, H. Bounameaux, and M. Prins Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants J Thromb Haemost 6 2008 227 229
62. J. Beyer-Westendorf, and H. Buller External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? J Thromb Haemost 9 2011 2153 2158
63. Philips Z Ouwens MJNM, and J.P. Jansen Network meta-analysis of parametric survival curves Res Synt Methods 1 2010 258 271
64. J.P. Jansen Network meta-analysis of survival data with fractional polynomials BMC Med Res Methodol 11 2011 61
65. J.P. Jansen, and S. Cope Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes BMC Med Res Meth 12 2012 1 16
66. S.A. Mitchell, T.A. Simon, and S. Raza The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematice review and meta-analysis Clin Appl Thromb Hemost 19 2013 619 631
67. A. Assiri, O. Al-Majzoub, and A.O. Kanaan Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation Clin Ther 35 2013 967 984
68. Bruins Slot KMH, Berge E, Saxena R, et al. Oral anticoagulants versus antiplatelet therapy for preventing stroke and systemic embolic events in patients with atrial fibrillation (Protocol). Cochrane Database Syst Rev 2012;Issue 2: Art. No. CD009538. 10.1002/14651858.CD009538
69. Mahtani KR, Heneghan CJ, Tai TW. Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation (Protocol). Cochrane Database Syst Rev 2012;Issue 4: Art. No. CD009787. 10.1002/14651858.CD009787.
70. Gauthier K., Bai B., Moulton K., et al. Antithrombotic agents for the prevention of stroke and other thrombotic events in patients with atrial fibrillation. Available from: http://www.crd.york.ac.uk/PROSPERO/display-record.asp?ID=CRD42012002721. [Accessed September 22, 2013].
71. N.J. Cooper, A.J. Sutton, and D. Morris Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation Stat Med 28 2009 1861 1881
72. J. Harenberg, S. Marx, and M. Wehling Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next? Thromb Haemost 108 2012 407 409
73. F.A. Achana, N.J. Cooper, and S. Dias Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta-analysis to network meta-analysis Stat Med 32 2013 752 771
74. Higgins JPT, Green SE, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: http://www.cochrane-handbook.org. [Accessed September 22, 2013]
75. S.G. Thompson, T.C. Smith, and S.J. Sharp Investigating underlying risk as a source of heterogeneity in meta-analysis Stat Med 16 1997 2741 2758
76. T. Tervonen, G. van Valkenhoef, and E. Buskens A stochasitic multicriteria model for evidence-based decision making in drug benefit risk-analysis Stat Med 30 2011 1419 1428